delgocitinib

FDA Drug Profile — Anzupgo

Drug Details

Generic Name
delgocitinib
Brand Names
Anzupgo
Application Number
NDA219155
Sponsor
LEO Pharma, Inc
NDC Codes
1
Dosage Forms
CREAM
Routes
TOPICAL
Active Ingredients
DELGOCITINIB

Indications and Usage

1 INDICATIONS AND USAGE ANZUPGO is indicated for the topical treatment of moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. ANZUPGO is a Janus kinase (JAK) inhibitor indicated for the topical treatment of moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. ( 1 ) Limitations of Use: Use of ANZUPGO in combination with other JAK inhibitors or potent immunosuppressants is not recommended. ( 1 ) Limitations of Use Use of ANZUPGO in combination with other JAK inhibitors or potent immunosuppressants is not recommended.